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Sua'mmary 
The current  understanding of the function of CD4 +  T  helper (Th)  cells in immunity to 
infectious diseases is that Thl cells, which secrete interleukin (IL)-2  and interferon-3,, induce 
cellular immune responses, whereas Th2 cells, which secrete IL-4, IL-5, IL-6, and IL-10, provide 
helper function for humoral immunity. We have used a panel of poliovirus-specific  murine 
CD4 + T cell clones and mice transgenic for the human poliovirus receptor to evaluate the role 
of Th cell subpopulations in protective immunity to poliovirus. The majority of T cell clones, 
as well as polyclonal T cells generated from mice infected or immunized with poliovirus, secreted 
IL-2 and interferon-q,, but not IL-4, IL-5, or IL-10, a profile typical of Thl cells. The Thl clones 
displayed major histocompatibility complex class II-restricted cytotoxic T lymphocyte activity 
against  specific poliovirus peptide-pulsed target ceils, but also provided help for antipoliovirus 
neutralizing antibody production. To examine the mechanism of immunity in vivo, we have 
used poliovirus receptor-transgenic mice on  a BALB/c  (H-2  a)  background.  These animals 
developed a poliomyelitis-like disease when challenged intravenously with a virulent wild-type 
strain of poliovirus, but not with an attenuated vaccine strain.  Furthermore, mice immunized 
with the vaccine strain were protected against a subsequent challenge with wild-type virus. Using 
an adoptive transfer technique, we demonstrated that it was possible to confer protection with 
primed B cells in the presence of polyclonal poliovirus-specific T cells, but not when transgenic 
mice received either B cells or T cells alone. Furthermore, protection was observed when mice 
received primed B cells in the presence of a VP4-specific Thl clone. The findings demonstrate 
that Thl cells can mediate a protective immune response against  poliovirus infection in vivo 
through helper activity for humoral immunity and that CD4 § T cells, specific for the internal 
poliovirus capsid protein, VP4, can provide effective help for a protective antibody response directed 
against  surface capsid proteins. 
C 
D4  T  cells have been divided into two populations 
termed Thl  and Th2 on the basis  of the profile  of 
cytokines secreted after antigen stimulation in vitro (1, 2). 
The Thl subpopulation secretes IL-2, TNF-3, and IFN-% 
whereas the Th2 subpopulation secretes IL-4, IL-5, IL-6, and 
IL-10. A current immunological  paradigm holds that the na- 
ture of an immune response is governed by the dichotomy 
that Thl cells mediate cellular immunity, delayed type hyper- 
sensitivity,  and inflammatory responses, and possibly direct 
lysis of virus-infected cells, whereas Th2 cells are considered 
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to be mainly responsible for the provision of specific T cell 
help for antibody production by B cells (1, 2). 
Poliomyelitis is an acute paralytic disease caused by infec- 
tion of the central nervous system  by virulent strains  of 
poliovirus, a member of the enterovirus genus of the picor- 
naviridae. The introduction of an inactivated poliovaccine (3) 
and of a live attenuated oral polio vaccine, developed by the 
late Albert Sabin (4), has led to a dramatic reduction in the 
occurrence of the disease. The resolution of the structure of 
the virus (5) and the elucidation of the complete nucleotide 
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virulence and attenuation (reviewed by P. D. Minor [7]). Virus- 
specific neutralizing antibody has been considered the major 
mechanism of protection against poliovirus infection. Con- 
sequently, the antigenic structure of the virus recognized by 
antibody has been well characterized. At least four neutralizing 
antibody epitopes have been identified and located on the three- 
dimensional structure of the virus particle (5, 7). In contrast, 
the possible role ofT cells in the protective immune response 
to poliovirus has received little attention. However, recent 
studies  of T cell recognition of poliovirus have identified a 
number of CD4 + T  cell epitopes,  using polyclonal T  cell 
populations (8-10).  Furthermore, we have used a panel of 
poliovirus-specific CD4 + T cell clones to characterize  T cell 
epitopes on each of the four capsid proteins of poliovirus and 
to identify amino acids critical  for T  cell recognition (11). 
These and other studies on heterotypic priming (12) provide 
circumstantial evidence of a role for T cells in immunity to 
poliovirus. If immunity against poliovirus is mediated through 
antibody responses, and, in particular, if secretory IgA in the 
gut plays a role in protection, it might be predicted that Th2 
would be involved in the protective mechanism. 
The recent development of transgenic mice bearing the 
human poliovirus receptor (PVR) 1 (13-15) and the establish- 
ment of poliovirus-specific  Th clones (11) has provided us 
with a convenient model to study the mechanism of immu- 
nity operating in a permissive  host in vivo. The findings of 
the present investigation demonstrate that the predominant 
cytokines secreted by poliovirus-stimulated spleen cells from 
either transgenic mice infected with attenuated poliovirus, 
immunized normal mice, or by poliovirus-specific  CD4 + T 
cell clones were IL-2 and IFN-3', a response that is character- 
istic of the Thl subpopulation. Although Thl clones  dis- 
played cytotoxic activity, adoptive transfer experiments demon- 
strated that poliovirus-specific Thl cells could confer protective 
immunity in vivo through the stimulation of neutralizing 
antibody production. The findings suggest that Thl cells can 
act  as true helper cells in immunity to viruses  in vivo. 
Materials and Methods 
Mouse  Immunizations  and  Challenge,  Mice of the  BALB/c 
(H-2  d) and CBA (H-2  k) strains were maintained as inbred colo- 
nies and used at 8-12 wk old. Transgenic mice which expressed 
the human  poliovirus receptor and H-2  a MHC class II genes, 
termed BALB/c  ~, were derived from ICR mice transgenic for the 
PVR. Normal BALB/c  mice were crossed  with ICR PVR Tgl mice 
(13, 15) and F1 hybrids expressing the PVR gene backcrossed  with 
BALB/c. The progeny  of the second  generation  were screened, using 
the polymerase chain reaction and restriction fragment polymor- 
phism analysis, for the presence of the H-2  a MHC class II and 
PVR genes. Transgenic mice were challenged intravenously with 
the virulent poliovirus type 3 Leon strain at doses between 1 x 
10  s and  1  x  10  s PFU/mouse.  A  concentration  of 1  x  10  7 
PFU/mouse of the type 3 Leon strain, >10x  LDs0  dose, was rou- 
t Abbreviation used in this paper: PVR, poliovirus receptor. 
tinely used for challenge. All mice were examined daily for 28 d 
after challenge and scored for paralysis. Mice which developed pa- 
ralysis in more than one limb were killed. In contrast, transgenic 
mice challenged  by oral inoculation failed  to show signs of  paralysis. 
In  active immunization  experiments,  normal  BALB/c or 
BALB/c  Pw mice received two intraperitoneal injections of 1 x  I0  s 
PFU Sabin type 3 poliovirus formulated in alum, 28 d apart. Alter- 
natively, BALB/c  ~  mice were infected  intravenously  with 1 x  107 
PFU of the attenuated Sabin type 3 vaccine strain. 
MHC-restricted  Poliovirus-specific T Cell Clones.  T cell  clones were 
established from the spleens of individual BALB/c or CBA mice 
immunized with the Sabin vaccine strains of poliovirus, as previ- 
ously described (11). The MHC restricting element for each clone 
was defined  in proliferation assays, using APC from congenic mice 
and syngeneic APC  preincubated with monoclonal antibodies 
specific for distinct class II molecules (16). 
Anal  m  ofCytokine Prodvxtion.  Spleen  cells (2  x  106/ml) from 
immunized BALB/c or infected BALB/c  Pv~ mice, or CD4 § T cell 
clones (1  x  10S/ml) and irradiated syngeneic spleen cells (2  x 
106/ml) were cultured with 1 x  108 PFU/ml poliovirus of the ap- 
propriate serotype or with medium alone as control. Supernatants 
were removed  after 24 h to determine ID2 and, after 72 h, to deter- 
mine IFN-% IL-4, II~5, and ID10. IL-2 release was assessed  by the 
ability of culture supernatants to support the proliferation of the 
IL-2-dependent cell line CTLL-2 as described (17), except that test 
samples were preincubated for 45 rain with 25 t~l of the anti-Ib4 
monoclonal  antibody 11-B-11 (National Cancer Institute, Frederick, 
MD) at a final concentration of 1.0/~g/ml to ablate responses to 
murine Ib4. Control cultures of the CTLD2 line with IL-4  in the 
presence of 11-B-11 showed complete abrogation of proliferation. 
Unitage was determined by reference to the CTLL proliferative 
responses obtained with a standard preparation of IIr2. Results are 
expressed as units per milliliter. The concentrations of murine Ib4, 
Ib5, IL-10, and IFN-3, were determined by ELISA using commer- 
cially  available  antibodies (PharMingen, San Diego, CA). Concen- 
trations were determined by comparing the OD492 for test samples 
with a standard curve for recombinant cytokines  of  known potency 
and concentration. 
In Vitro CTL Assay.  T cell clones were tested for in vitro CTL 
activity using a standard technique (18) modified as follows: T call 
clones were harvested 10-12 d after antigen stimulation, washed, 
and counted. The target cells, A20.2J (H-2  a) and CH1 (H-2k), 
were labeled with sodium [SlCr]-chromate (Amersham Interna- 
tional, Little Chalfont, UK) and incubated with peptides (0.4-10 
/~g/ml), corresponding to the sequence of Sabin type 3 poliovirus 
VP1:257-268 or VP4:16-30. Labded target cells (1  x  104) were 
incubated with varying numbers of T cells to give effector/target 
ratios of 20:1-1:1. The percentage of specific lysis was determined 
after 6-8 h, as described (18). Spontaneous release usually ranged 
between 10 and 20% of maximum release, and assays, in which, 
the spontaneous  release exceeded  20% of the maximum release  were 
discarded. Results presented are the arithmetic means of three 
cultures. 
Determination of Poliovirus-specific Antibody Titers.  The titers of 
poliovirus-specific neutralizing  antibody  were determined  by 
microneutralization  assay,  as described (19). Each test was performed 
in quadruplicate and the results taken as the reciprocal of the final 
dilution that totally inhibited a viral cytopathic effect. Results are 
expressed as geometric mean titers of at least two titrations. The 
IgG subclass  of  poliovirus-specific  antibody was determined, using 
an immunoassay. Purified poliovirus-specific rabbit IgG diluted 
1/1,000 in PBS was added (50 t~l/well) to Maxisorp-Immunoplates 
(Gibco, Ltd., Paisley, UK). Plates were then incubated overnight 
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was discarded, and the plates washed four times in 0.1% (vol/vol) 
Tween 20 in PBS before the addition of 200/~l/well 5% (wt/vol) 
milk powder in PBS and incubation at 35~  in a humidified incu- 
bator for 1 h. Plates were then washed six times before incubation 
for 3 h  at 35~  with 50 #l/well poliovirus at ,,o0.5/~g/ml and 
of matched serotype to the specificity of the capture antibody. Un- 
bound virus was then discarded, and the plates washed six times 
before incubation for 2 h with serum samples at various dilutions. 
Plates were again washed six times before a 30-min incubation with 
50/~l/ml of 1/1,000 diluted horseradish peroxidase-conjugated de- 
tecting antibodies specific for murine IgG subclasses.  Plates were 
washed a further six times and incubated for 45 rain with 50 #l/well 
of freshly prepared 1 mg/ml o-phenylenediamine (Sigma Chemical 
Co., Poole, UK) in citrate-phosphate buffer supplemented with 1 
/~l/ml FI202.  The reaction  was stopped by the  addition  of 50 
#l/well 1 M  H2SO4,  and the OD+92 measured using a Multiskan 
+  plate reader (ICN Flow, High Wycombe, Bucks, UK). Control 
wells in which either capture antibody, virus, sample, or detecting 
antibody had been systematically omitted showed only background 
readings at OD+gz. 
Isolation of  Polyclonal T and B Cell Populations.  Enriched B cells 
were prepared from the spleens of poliovirus-immunized BALB/c 
mice. Spleen cells were washed once (5-min centrifugation at 300 
g),  and  the  pellet  resuspended  at  1  x  10  ? cells/ml  in  filter- 
sterilized GK1.5 tissue culture supematant, to which sterile anti-Thy 
1.2 ascitic fluid had been added (final dilution 1/200). After incu- 
bation on ice for 45 rain, the cells were washed three times in serum- 
free medium before resuspension at 1  x  10  ? cells/ml in agarose- 
absorbed guinea-pig complement (Cedarlane Laboratories Ltd., 
Hornby, Canada) diluted to 1/16 in serum-free medium. The cells 
were incubated for 1 h at 37~  and then washed three times in 
complete medium. 
T  cell purification was performed using a T  cell isolation kit 
(IsoCell; Pierce Chemical Co., Rockford, IL) or T  cell isolation 
columns (Immulan; Biotex Laboratory Inc., Houston, Texas), as 
described by the manufacturers. Briefly, columns were charged with 
an avid  anti-mouse Ig reagent bound  to an inert  support,  the 
columns were washed, and spleen cell preparations loaded. An en- 
riched T cell population was obtained from the column by elution 
with PBS, either directly (Immulan), or after a 1-h incubation at 
room temperature (IsoCell). The purity of B and T  cell prepara- 
tions was monitored by FacScan |  analysis of 50-/~1 samples of the 
cell preparations before and after treatment, using goat anti-mouse 
Ig-FITC (B cells) or anti-mouse Thy 1.2 (T cells). All preparations 
used contained <1% contamination of the depleted population. 
Determination ofT Cell Helper Function.  The ability of poliovims- 
specific T  cell clones or primed polyclonal T  cell popuhtions  to 
provide help for pollovims-specific antibody production in vivo was 
determined using an adoptive transfer technique.  Recipient BALB/c, 
CBA, or BALB/c" mice were irradiated with a sublethal dose of 
6 Gy total body irradiation by exposure to a Gammacell 2,000 
137Cs source  (Molsgaard  Medical,  Horsholm,  Denmark).  18  h 
later,  the irradiated mice were selectively reconstituted with com- 
binations of 1  x  10  ? primed or naive B cells and 1  x  10  ? primed 
or naive T  cells or 1  x  10  + T  cell clones in either the presence 
or absence of virus. Control mice were reconstituted with spleen 
cell preparations from naive mice. 14 d later, mice were killed, and 
the serum was collected and assayed for poliovirus-specific antibody. 
Protection Studies in 7~ans  genic Mice.  In active immunization ex- 
periments, transgenic mice were injected intravenously with two 
doses of I  x  10  ? PFU/mouse of the attenuated Sabin type 3 strain 
of poliovirus at weeks 0 and 4. 2 wk later, a small quantity of blood 
was removed for serum antibody analysis, and mice were challenged 
with the virulent Leon type 3 strain.  In a passive immunization 
study,  groups of BALB/c  ~  mice received 0.2 ml of high titer neu- 
tralizing serum by intravenous injection. The serum was isolated 
from BALB/c mice which had previously received two immuniza- 
tions of Sabin  type 3 poliovims in alum. Control mice received 
0.2 ml serum derived from naive mice. Mice were challenged 6 h 
later with a lethal dose of virulent poliovirus and followed for signs 
of paralysis. 
In initial adoptive transfer experiments designed to define the 
role of lymphocyte subpopulations in protection, BALB/c  "~ mice 
were irradiated, reconstituted after 24 h with either immune spleen 
cells or combinations of immune T  and B cells, and challenged 
6 h later. These mice all developed paralysis. In subsequent experi- 
ments, lethal challenge was delayed by 7 d to allow the develop- 
ment of a protective immune response. Transgenic mice were recon- 
stituted with B and T cells, purified from the spleens of immune 
mice as described above,  together with  1  x  106 PFU/mouse of 
Leon type 3 virus, which had been heat inactivated at 56~  for 
40 min. 7 d later, all animals were challenged with a lethal dose 
of Leon type 3 poliovirus after the collection of a small sample of 
serum for analysis of neutralizing antibody titers. Mice were exam- 
ined daily and scored for paralysis. 
Results  and  Discussion 
Lack of expression of the PVR by nonprimate species has 
precluded the use of a small animal model for studies of im- 
munity to poliomyelitis.  However,  the recent development 
of transgenic  mice bearing  the  human  poliovirus  receptor 
(13-15) has provided us with a convenient small animal model 
for studies  of immunity  against poliovirus  in  a permissive 
host. Transgenic mice expressing the PVR and homozygous 
Table  1.  Active or Passive Immunization  Protects BALB/c  ~w 
Transgenic Mice against a Lethal Poliovirus Challenge 
Neutralizing  Onset 
Immunization*  Ab titer*  Challenge  paralysis  (d)S Survival 
-  <1/10  Sabin  3  -  4/4 
_ H  <1/10  Leon 3  3-4  0/6 
Active  1/1,448  Leon 3  -  3/4 
1/64 
1/1,448 
1/11  4 
Passive  1/1,280  Leon 3  -  6/6 
* Groups  of BALB/c  Pv" transgenic mice were  either  untreated,  im- 
munized with 1  x  108 PFU of Sabin type 3 poliovirus in alum 14 and 
42 d before challenge, or received 0.2 ml serum from naive or immune 
mice 6 h before challenge. 
Neutralizing  antibody titer  was determined either on blood samples 
taken at the time of challenge, or on the serum samples used for passive 
immunization. 
S Results are expressed as the mean day of onset of paralysis within the 
mice showing  signs of paralysis for each group. 
II Mice received either no pretreatment,  or were injected with serum 
from normal naive BALB/c mice. 
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BALB/c ~v" Mice 
Cytokines* 
MHC 
T  cells  restriction  Specificity*  IL-2  IFN-'y  IL-4  IL-5  IL-10 
Clones  U/ml  ng  /ml  pg  /ml  pg  /ml  pg  /ml 
3N2s5.1  I-E  d  VP1:257-264  <0.05  2  500  150  180 
CB2.2-5  I-A  k  VP3:14-28  1.92  47  <50  <50  <70 
2KB-3  I-A  k  VP3:14-28  2.07  55  <50  <50  <70 
2KB-6  I-E  k  VP3:196-210  3.15  90  230  >103  150 
CB2.2-3  I-A  k  VP3:14-28  2.05  100  <50  <50  <70 
CB2.2-10  I-E  k  VP3:189-203  0.83  51  <50  <50  <70 
1N5-1  I-A  d  VP4:16-25  2.20  53  <50  <50  <70 
1N8.44  ND  ND  <0.05  45  240  120  140 
CB2.1-3  I-E  ~  VP4:21-35  1.94  80  <50  <50  <70 
CB2.1-6  I-E  k  VP4:21-35  1.66  32  <50  <50  <70 
CB2.2-4  I-A  k  VP4:5-20  <0.05  49  200  210  100 
2KA-1  I-A  k  VP4:11-25  3.02  100  <50  <50  <70 
2KA-2  I-E  k  VP4:21-35  1.26  66  <50  <50  <70 
2KA-5  I-E  k  VP4:21-35  1.17  52  <50  <50  <70 
2KB-4  I-A  k  VP4:11-25  0.93  68  <50  <50  <70 
3KC-1  I-A  k  VP4:11-25  0.51  100  <50  <50  <70 
Spleen cellsS 
BALB/c  H-2  a  Polyclonal  3.2  >100  <50  100  <70 
BALB/c  ~v'  H-2  a  Polyclonal  1.1  >I00  <50  <50  <70 
" The Poliovirus serotype, capsid protein, and peptide specificity  of the T cell clones have previously  been described (11). 
* Cytokine levels were assayed in supernatants of T cell clones stimulated with poliovirus  in the presence  of irradiated syngeneic  APC. Results are 
the mean of triplicate assays, performed  in duplicate. 
S  Spleen cells were derived from BALB/c mice immunized with Sabin type 3 virus in alum or BALB/c  Pv~ mice infected with Sabin type 3 virus. 
for  Ia  a genes  developed a  poliomyelitis-like disease  when 
challenged intravenously with a virulent wild type strain of 
poliovirus (Leon type 3), but not with the attenuated Sabin 
type 3 strain (Table 1). Furthermore, PVR transgenic mice 
immunized with the vaccine strain formulated in alum were 
protected against a subsequent challenge with wild type virus 
(Table  1). Thus, the rules governing virus attenuation and 
the development of a protective immune response appear to 
be similar in both primates (20) and transgenic mice (13-15). 
The transgenic mice used in the present study were de- 
rived from outbred ICR PVR Tgl mice (13, 15) which were 
backcrossed with BALB/c mice for two generations and in- 
dividual offspring screened for the expression of  BALB/c MHC 
and  poliovirus  receptor  genes.  Consistent  with  previous 
findings in the PVR transgenic mouse models (13-15), it was 
not possible to reproducibly demonstrate infection in the gut 
after oral inoculation.  However, the choice of intravenous 
challenge was relevant to the induction ofviremia in poliomye- 
litis and resulted in consistent development of paralysis and 
death of transgenic mice. This was found to be the most con- 
sistent and unambiguous end point of infection in a nonim- 
mune host. The limited number of mice available precluded 
studies on the kinetics of viral replication. Nevertheless, the 
development of single MHC haplotype FVR transgenic mice 
and the generation of MHC-compatible poliovirus-specific 
T cell clones has allowed us to examine for the first time the 
role of T  cells in immunity to poliovirus, which had been 
impossible in previous animal models of poliomyelitis. 
Since antipoliovirus antibodies are considered to be crit- 
ical in protective immunity against poliovirus infection, it 
might be predicted that Th2 cells could play an important 
role in the protective mechanism. However, our study demon- 
strated that poliovirus-specific  murine CD4 + T cells induced 
by either immunization of normal BALB/c mice or infection 
of transgenic mice are predominantly of  the Thl profile (Table 
2). An examination of the cytokines released by a panel of 
MHC class  II-restricted CD4 + T  cell clones,  specific  for 
defined epitopes on poliovirus capsid proteins VP1, VP3, or 
VP4 (11), revealed  that  12 out of 16 clones produced IL-2 
and IFN-% but not IL-4, IL-5, or IL-IO after specific an- 
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2KB-6, 1N8.44, and CB2.2-4, did not conform to either the 
Thl or Th2 classification. These clones consistently secreted 
IL-4, IL-5, IL-10, high levels of IFN-'y,  and in the case of 
done 2KB-6, IL-2, and may therefore belong to the Th0 sub- 
population (1). Clone 3N2s5.1 secreted IL-4, IL-5, and IL-10, 
but  not  IL-2,  and only low levels  of IFN-'),,  an  atypical 
cytokine profile. A number of parameters, including the choice 
of adjuvant, dose, and route of immunization and the form 
of the antigen (particulate versus soluble, replicating versus 
killed), may influence the induction of distinct Th cell sub- 
populations (21-23).  However,  the predominant cytokines 
detected in the supernatants of poliovirus-stimulated spleen 
cells derived from either transgenic mice infected with Sabin 
type 3 virus or normal BALB/c mice immunized with inac- 
tivated virus, with or without alum, by systemic or intranasal 
routes, were IL-2 and IFN-3' (Table 2 and data not shown). 
The selective induction of Thl ceils in mice is not compat- 
ible with the perceived importance of mucosal antibodies in 
immunity to poliovirus in man. However, it is possible that 
oral immunization with attenuated poliovirus vaccine, which 
is known to induce an antipoliovirus mucosal IgA response 
in  humans  (24),  may  favor  the  induction  of  Th2  cells. 
Nevertheless, our findings suggest that inactivated poliovirus 
vaccines, which are also highly effective at conferring protec- 
tive immunity against poliovirus infection in humans (25), 
may preferentially generate Thl  cells. 
An examination of the function of the CD4 + poliovirus- 
specific T  cell clones in vitro revealed that clone 1N5.1 and 
all other Thl danes were capable of lysing MHC-matched, 
but not mismatched, target ceils pulsed with specific polio- 
virus peptides (Fig. 1 A). Significant lysis of target cells was 
observed at an effector to target ratio of 1:1 using a peptide 
concentration of 10 #g/ml (Fig.  1 C).  However, CTL ac- 
tivity could not be demonstrated for clone 3N2s5.1 (Fig.  1 
B). This finding is consistent with other studies which have 
associated Thl ceils with classical cdlular immune responses 
(1, 2). However, our study demonstrated that the poliovirus- 
specific Thl cells could also provide hdp for B cell produc- 
tion of antibody. Polyclonal poliovirus-specific T ceils, which 
secreted predominantly IL-2 and IFN-'y (Table 2), stimulated 
antipoliovirus antibody production by immune B cells in viva 
(Fig. 2) and in vitro (data not shown). Furthermore, adop- 
tive transfer techniques revealed that both Thl and Th0 clones 
could provide help in viva for the production of poliovirus- 
specific neutralizing antibody production (representative ex- 
amples  shown  in  Fig.  2).  In  other  murine  systems,  the 
cytokines IL-4,  IL-5,  and IL-6 have been shown to play a 
role in the provision of help to B cells, in particular for IgG1, 
IgG3,  IgA,  and  IgE  production  by  controlling  Ig  class 
switching and B cell differentiation (1, 26). However, in vitro 
studies with B ceils stimulated with mitogens or model an- 
tigens have also shown that IFN-'y can augment an IgG2a 
response (27).  In the present study, the predominant sub- 
class of poliovirus-specific IgG produced through the helper 
function of Thl cells and in the serum of poliovirus-immunized 
normal mice or infected transgenic mice was IgG2a (Fig. 3). 
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Figure 1.  Cytotoxic  activity  ofpoliovirus-specific  Thl clones. The CTL 
activity of MHC class II-restricted T cell clones 1N5.1 (A) and 3N2s5.1 
(B) was determined  in vitro against MHC-matched  A20.2J(H-2  d) and mis- 
matched CHI(H-2  k) target cells incubated  with peptides  (1 #g/m1), cor- 
responding to the sequence of Sabin poliovirus type 3 VP4:16-30 or 
VP1:257-268. (C) CTL activity of clone 1N5.1 against MHC-matched 
A20.2J target cells incubated with either no peptide, or with 0.4, 2.0. 
or 10.0 #g/ml of peptide VP4:16-30. 
Furthermore, an increased antipoliovirus antibody response 
was observed when primed B cells were cultured with IFN-% 
Therefore, our findings demonstrate that Thl calls, through 
the secretion of IFN-3', may mediate T cell help for a protec- 
tive antipoliovirus IgG2a antibody response. Although the 
consensus view has been that Thl cells mediate cell-mediated 
immunity, while Th2 cells mainly stimulate humeral immu- 
nity, our demonstration of helper function by Thl cells in 
viva is supported by a study of an enveloped virus, influenza 
virus, which also demonstrated that Thl clones could pro- 
vide help for B cell production of antibody (28). 
1289  Mahon  et ai. 10000 
_.= 
I- 
1000 
r-@ 
~z 
100 
,r 
B cells  B+T cells  B+I N5.1  B+3N2s5,1 
r////~//// 
////////// 
/  /  ///i//// 
i  /  ///////i 
////////// 
////////// 
////////// 
/  /  /  / ......  /////////A 
....  "  .....  "/////////A 
~11111111/ 
"  "  /  / ......  l/l/l/IliA  .......... 
~]/]l///// 
/11111111/  ~IIIIIIIIA 
III//11~// 
i  ￿9 
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Figure  2.  Thl  cells  provide 
hdper function in vivo for polio- 
virus-specific neutralizing antibody 
production￿9  Irradiated  BALB/c mice 
were reconstituted with primed B 
cells  and  inactivated  poliovirus, 
alone, or in combination with ei- 
ther polyclonal immune T cdls, T 
call done  1N5.1,  or T  cell clone 
3N2s5.1.  The titer  of poliovirus- 
specific neutralizing antibody was 
determined in the serum 14 d after 
reconstitution.  The  neutralizing 
antibody titers are also shown for 
serum samples  from normal BALB/c 
mice immunized twice with Sabin 
type 3 poliovirus in alum and for 
BALB/c  ~'~ transgenic mice infected 
with Sabin type  3  poliovirus.  <, 
titer less than  1/100. 
The  availability  of  PVR  transgenic  mice  and  MHC- 
compatible, poliovirus-specific,  MHC class II-restricted  T cell 
clones allowed us to examine the role of CD4 §  T  cells in 
protection against  a lethal poliovirus challenge in vivo. Our 
first challenge experiments confirmed the suggestions from 
studies carried out in primates over 40 yr ago that neutralizing 
antibodies can protect against poliovirus infection (29). Pro- 
tection induced by active immunization was found to corre- 
late with the level  of neutralizing  antibodies in the serum 
at the time of challenge (Table 1). Furthermore, passive transfer 
of high titer poliovirus-specific  antibody into transgenic mice 
conferred protection against a lethal challenge with Leon type 
3 poliovirus (Table 1).  In contrast,  adoptive transfer of im- 
mune spleen cells into sublethally irradiated transgenic mice, 
followed by immediate challenge, resulted in mice succumbing 
to paralysis 3-4 d later  (data not shown).  However, when 
challenge was delayed until 7 d after transfer of immune spleen 
cells (together with an inactivated poliovirus to stimulate the 
transferred T cells), protection was observed (Table 3). This 
finding demonstrated that immunity could be transferred using 
immune spleen cells,  but that a period of 7 d was required 
to allow the development of the protective immune response. 
Furthermore,  protective immunity was a function of the cells 
transferred, not a primary response to the inactivated  virus, 
as control mice, which received inactivated  virus and either 
naive spleen cells or no cells,  were not protected (Table 3). 
The involvement of both memory T and B cells in protec- 
tive immunity to poliovirus was demonstrated in adoptive 
transfer experiments using purified or cloned populations of 
lymphocytes.  BALB/c ~w mice that received  primed B cells, 
in combination with either polyclonal immune T cells or a 
poliovirus-specific  I-Aa-restricted T cell clone 1N5.1,  devel- 
oped moderate to high  titers  of neutralizing  antibody and 
were protected against  a lethal infection with the virulent 
Leon strain when challenged 7 d after cell transfer￿9 In con- 
trast, mice which received T cells or B cells alone were not 
protected.  An examination of poliovirus-specific  neutralizing 
antibody responses in mice that received B cells alone before 
challenge (Table 3) and on paralysis showed that they mounted 
a weak or undetectable  humeral  response.  These findings 
demonstrate  the critical  role of T  cells  in providing  help 
for a protective antibody response to poliovirus and also sug- 
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Figure 3.  IgG2a  is the predominant IgG 
subclass of antipoliovirus antibody￿9 Irradi- 
ated BALB/c mice were reconstituted with 
primed B cells and inactivated poliovirus, 
alone, or in combination with either poly- 
donal immune T cells, T cell clone 1N5.1, 
or T cell clone 3N2s5.1. The lgG subclass 
of poliovirus-specific antibody present in 
serum 14 d after reconstitution was deter- 
mined by specific ELISA. The isotype  of 
poliovirus-specific antibody present in the 
serum of normal BALB/c mice immunized 
twice with Sabin type 3 poliovirus in alum 
and in serum from BALB/c Pv= transgenic 
mice infected with Sabin type 3 poliovirus 
are also shown. < denotes a titer less than 
1/100. 
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Mice after Adoptive Transfer of Thl  Cells in the Presence of 
Primed B Cells 
Cell Transfer* 
Neutralizing  Onset 
T Cells  B Cells  Ab Titer*  Paralysis (d)S Survival 
-  --  <1/10  5  0/8 
Naive  Naive  <1/10  4  0/6 
Immune  -  <1/10  7  0/6 
Clone 3N2s5.1  -  <1/10  6  0/5 
Clone 1N5.1  -  <1/10  5  0/5 
-  Immune  <1/10  8  1/6 
Immune  Immune  1/350  7  5/6 
Clone 3N2s5.1  Immune  1/70  6  4/6 
Clone 1N5.1  Immune  1/290  -  6/6 
* Irradiated BALB/c  -R transgenic mice were reconstituted with com- 
binations of polyclonal  B or T cells purified  from spleens of immune  mice 
or poliovirus-specific  CD4 + T cell clones, together with 1 x  10  6 PFU 
heat-inactivated Sabin type 3 poliovims. Control mice received inacti- 
vated virus alone, or inactivated  virus and purified B and T cells from 
naive BALB/c  mice. 
* Neutralizing antibody titers were determined in serum from blood 
samples taken immediately  before challenge. 
S  Results are expressed as the mean day of onset of paralysis  within the 
mice showing signs of paralysis for each group. 
gest that neuronal damage observed in poliomyelitis is un- 
likely to  result  from T  cell-mediated immunopathology. 
The observation that transfer of T  cells in the absence  of 
B cells failed to prevent poliovirus-induced paralysis suggests 
that direct cellular erector mechanisms alone,  such as cyto- 
toxicity, are insufficient to confer protective immunity. How- 
ever, this does not eliminate a role for CTL in viral clearance 
or for IFN-3, in limiting viral spread.  The significance  of 
the demonstrated in vitro cytotoxic function of the polio- 
virus-specific  Thl  clones (Fig.  1)  to immunity in vivo is 
unknown, but may be a mechanism for the downregulation 
of an active immune response (30). 
Our findings indicate that protection can be mediated by 
a T cell clone specific for an epitope on VP4. Since VP4 is 
a conserved internal protein which is not known to be a target 
of the humoral immune response (7), this study demonstrates 
that Thl cells can play a critical role in protective immunity 
against a lethal viral infection through the provision inter- 
molecular, intrastructural help (31). Although this phenomenon 
is not universal  (32),  it is supported by observations from 
both the influenza and hepatitis B virus systems (33, 34) and 
has important implications for the role of cross-reactive  T 
cells in priming the poliovirus-specific immune response (12). 
For example,  it may be possible to exploit this observation 
to reduce the incidence of vaccine-associated  cases of poliomye- 
litis attributed to the type 3 component of the oral poliovac- 
cine. Immunization with a single poliovirus serotype, or with 
purified or recombinant VP4, would prime for an anamnestic 
antibody response to other serotypes after a booster with the 
trivalent vaccine. 
The observation that adoptive transfer of primed B cells 
with the Thl done 1N5.1 conferred 100% protection, whereas 
clone 3N2s5.1, which secretes low levels of IFN-% protected 
four out of six mice, adds further evidence to the role of IFN-3' 
in stimulating a protective IgG2a antibody response. Whilst 
Thl cells have been largely associated with cdlular responses, 
especially against bacterial pathogens (1, 2,  35),  this study 
dearly demonstrates their role in directing protective humoral 
immunity against viruses and may explain the IgG2a restric- 
tion of murine antibodies elicited by viral infections (36, 37). 
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